Phase 2 RCT | Deintensified chemoradiotherapy for pretreatment Epstein-Barr Virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma.

Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentaries:

#VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma – Physician’s Weekly

Intensity-Modulated Radiotherapy Plus 2 Cycles of Concurrent Cisplatin Improved Low-Risk LA-NPC Outcomes – Cancer Network

Commentary on Twitter

Less is more? ? 2-cycle cisplatin concurrent chemoradiotherapy is not inferior to 3-cycles based on 3-yr PFS in treating locoregionally advanced nasopharyngeal ca w/preRX EBV DNA levels < 4000.QOL & toxicity improved w/ less chemo https://t.co/XovHi2P06W pic.twitter.com/JJqiC8wnWW

— Journal of Clinical Oncology (@JCO_ASCO) January 25, 2022